Exxon profits slump 56%, joins global peers in energy price hit
By Sabrina Valle HOUSTON (Reuters) -Exxon Mobil’s <XOM.N> second-quarter profit dropped 56% and fell short of Wall Street expectations, the…
2023
Chipmakers signal supply glut easing but demand recovery still slow
By Joyce Lee SEOUL (Reuters) -From Intel to Samsung, global chipmakers are celebrating the beginning of the end of a…
Shipping group CMA CGM braced for weaker profit before demand picks up in 2024
PARIS (Reuters) – French shipping group CMA CGM expects container freight demand to improve from next year but the group’s…
Biogen to buy Reata for $6.5 billion to bulk up rare disease portfolio
By Manas Mishra and Bhanvi Satija (Reuters) -Biogen agreed to buy rare disease drugmaker Reata Pharmaceuticals for nearly $6.5 billion,…
Laurentian Bank’s shares fall after media report that potential top bidders bowed out
(Reuters) – Laurentian Bank of Canada’s shares fell 9% on Friday after a newspaper reported that the Montreal-based bank was…
AstraZeneca’s rare disease arm in $1 billion deal for Pfizer gene therapies
By Yadarisa Shabong (Reuters) -AstraZeneca said on Friday its Alexion unit had agreed to buy U.S. drugmaker Pfizer’s early-stage rare…
Centene aims to enroll back some lost Medicaid members
By Mariam Sunny and Leroy Leo (Reuters) -Centene Corp said on Friday it was working to enroll people back into…
Drugmakers go under the skin, skirting early US Medicare price negotiations
By Michael Erman NEW YORK (Reuters) – Injectable versions of some widely-used cancer drugs including Johnson & Johnson’s blockbuster multiple…
Softening inflation props up U.S. consumer sentiment
By Safiyah Riddle (Reuters) – Diminishing inflation pushed consumer sentiment to the highest in nearly two years, a closely watched…
Brazil set to kick off monetary easing with small rate cut on Aug 2: Reuters poll
By Luana Maria Benedito and Marcela Ayres SAO PAULO (Reuters) – Brazil’s central bank is poised for its first interest…